Results 161 to 170 of about 3,859 (214)

Thrombocytopenia and Vomiting Due to Difluoromethylornithine

Drug Intelligence & Clinical Pharmacy, 1987
A 32-year-old Haitian male with acquired immunodeficiency syndrome presented with complications of Isospora belli enteritis. Therapy with the investigational drug difluoromethylornithine was initiated. Severe thrombocytopenia, nausea, and vomiting developed during intravenous drug therapy and recurred upon rechallenge with low-dose oral ...
K J, Tietze, J A, Gaska, E M, Cosgrove
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Difluoromethylornithine in Cancer: New Advances

Future Oncology, 2017
Difluoromethylornithine (DFMO; eflornithine) is an irreversible suicide inhibitor of the enzyme ornithine decarboxylase which is involved in polyamine synthesis. Polyamines are important for cell survival, thus DFMO was studied as an anticancer agent and as a chemoprevention agent. DFMO exhibited mainly cytostatic activity and had single agent efficacy
Georgios D Lianos, Vasiliki Galani, George A Alexiou   +2 more
exaly   +3 more sources

Plasmodium berghei: Inhibition of the Sporogonous Cycle by α-Difluoromethylornithine

Experimental Parasitology, 1983
alpha-Difluoromethylornithine (DFMO), an enzyme inhibitor of ornithine decarboxylase, inhibits the sporogonous cycle of the malaria parasite Plasmodium berghei in the mosquito vector Anopheles stephensi. DFMO was administered to the mosquitoes dissolved either in the sugar solution at their disposal in the cages or through blood meals taken from ...
Jacqueline Charlier
exaly   +3 more sources

Differential Effects of Difluoromethylornithine on Basal and Induced Activity of Cerebral Ornithine Decarboxylase and mRNA [PDF]

Neuropharmacology, 1991
The induction of the activity of cerebral ornithine decarboxylase (EC 4.1.1.17) and mRNA by electrical stimulation exhibits regional differences. The effects of the enzyme inhibitor difluoromethylornithine on these regional variations was examined ...
S C Bondy
exaly   +2 more sources

Irreversible Ototoxicity Associated with Difluoromethylornithine

Cancer Epidemiology, Biomarkers & Prevention, 2004
Abstract Difluoromethylornithine (DFMO) is a potent, irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme in the synthesis of polyamines that promote cellular proliferation. DFMO has been tested as a potential cancer therapeutic and chemopreventive agent in clinical trials.
Christopher D, Lao, Patricia, Backoff, Lawrence I, Shotland, Deborah, McCarty, Tracy, Eaton, Frank G, Ondrey, Jaye L, Viner, Stuart Jon, Spechler, Ernest T, Hawk, Dean E, Brenner   +9 more
openaire   +2 more sources

Antitrichomonal activity of α-difluoromethylornithine

Journal of Antimicrobial Chemotherapy, 1987
alpha-Difluoromethylornithine, an inhibitor of polyamine biosynthesis, affected the pathogenicity of Trichomonas vaginalis in two model systems. Firstly, it blocked the cytotoxic effect of the parasite towards mammalian cells in culture: at a concentration of 1 mM it prevented the death of mouse myeloma cells in mixed culture with trichomonads ...
A F, Bremner, G H, Coombs, M J, North
openaire   +2 more sources

Difluoromethylornithine inhibits crypt fission

Gastroenterology, 1998
Crypt fission is a physiologic mechanism of crypt reproduction. It increases in pathophysiologic situations where intestinal regeneration is required (e.g., radiation injury). Polyamine metabolism is important in the regulation of intestinal growth and recovery from injury in response to a variety of stimuli. Our aim was to determine whether inhibition
J S, Thompson, S K, Saxena, J G, Sharp
openaire   +2 more sources

Radiosensitization of human tumor cells by alpha‐difluoromethylornithine

International Journal of Cancer, 1986
AbstractThe effect of polyamine depletion on the radiosensitivity of a human tumor cell line was investigated. CAL 18 A cells, derived from a breast carcinoma, were incubated with alpha‐difluoromethylornithine (DFMO)—a specific and irreversible inhibitor of ornithine decarboxylase (ODC)—at a 1 mM or 10‐mw concentration for either 1 hr or 24 hr and ...
A, Courdi, G, Milano, M, Bouclier, C M, Lalanne   +3 more
openaire   +2 more sources

Preventive treatment of rabbit coccidiosis with α-difluoromethylornithine

Veterinary Parasitology, 1988
The effect of alpha-difluoromethylornithine (DFMO) administered in drinking water (0.2 and 0.5%) against liver and intestinal coccidioses in experimentally infected rabbits was studied. Zootechnical and clinical parameters were used to assess the efficacy of the compound. In both coccidioses the lower dose did not show any important effect.
B V, San Martín-Núñez, D, Ordóñez-Escudero, J M, Alunda   +2 more
openaire   +2 more sources

Problems of pharmacokinetic studies on alpha-difluoromethylornithine in mice

Cancer Chemotherapy and Pharmacology, 1987
The pharmacokinetics of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of polyamine biosynthesis, were investigated in BALB/c (nude) mice after i.p. injection and after oral administration of radiolabeled drug. After i.p. injection the compound was rapidly cleared from the serum (t1/2 alpha = 14 min; t1/2 beta = 2.1 h) and from tissues
J C, Romijn, C F, Verkoelen, T A, Splinter   +2 more
openaire   +2 more sources